Table 2. Summary of the BAP1 immunohistochemistry and genotyping results of the tumors included in the study.
| HCC No=51 | ICC No=8 | CBD No=2 | PDAC No=37 | AC No=5 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative | Weak | Positive | Negative | Positive | Negative | Positive | Negative | weak | Positive | Positive | ||
| BAP1 IHC Number % | 3(5.9%) | 6(11.8%) | 42(82.41%) | 4(40%) | 4(40%) | 0 | 2(100%) | 1(2.4%) | 5(13.5%) | 30(81.08%) | 5(100%) | |
| LOH frequencies* | 2(66.6%) | 4(66.7%) | 21 (53.8%) | 4(100%) | 2(50%) | 0 | 2(100%) | 1(100%) | 4(10.8%) | 11(36.6%) | 1(20%) | |
| D3S3630 | 3p26.3 | 2(66.6)%) | 4(66.7%) | 13 (41.9%) | NA | NA | NA | NA | 0 | 2(5.4%) | 2(5.4%) | 0 |
| D3S1578 | 3p21.1 | 1(33.3)%) | 3 (33.3%) | 10(40.%) | NA | NA | NA | NA | 1(100%) | NA | 5(13.5%) | 0 |
| D3S3561 | 3p21.1 | 1(33.3%) | 4(80%) | 9(31%) | 4(100%) | 1 (25%) | 0 | 1(50%) | 0 | NA | 2(5.4%) | 0 |
| D3S3026 | 3p21 | 1(33.3%) | 2(40%) | 12(35.3%) | 2(50%) | 2(50%) | 0 | 0 | 1(100%) | 5(100%) | 0 | 1(20%) |
| D3S3644 | 3p14.1 | NA | 1(25%) | 12(42.9%) | 4(100%) | 2(50%) | 0 | 0 | 0 | NA | 2(5.4%) | 0 |
LOH: loss of heterozygosity, markers are sorted from telomeric to centromeric.
Note, Percentages represent samples with informative markers, non-informative markers were excluded.